EGFR – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of epidermal growth factor receptor (EGFR)-mutated tumors comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of EGFR-mutated cancer for each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s EGFR forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of EGFR over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 43 EGFR patient populations:
- Diagnosed incident cases of EGFR-mutated non-small-cell lung cancer (NSCLC).
- Diagnosed incident cases of metastatic EGFR-mutated NSCLC.
- Diagnosed incident cases of nonmetastatic EGFR-mutated NSCLC.
- Diagnosed incident cases of EGFR-mutated NSCLC by exon subtype (exon 18 / 19 / 20 / 21).
- Diagnosed first-line drug-treatable cases of EGFR-mutated breast cancer.
- Diagnosed recurrent incident cases of EGFR-mutated colorectal cancer.
- Diagnosed incident cases of metastatic EGFR-mutated squamous cell carcinoma of the head and neck (SCCHN).
- Diagnosed incident cases of EGFR-mutated small-cell lung cancer (SCLC).
- Diagnosed incident cases of nonmetastatic EGFR-mutated colorectal cancer.
- Diagnosed incident cases of EGFR-mutated glioblastoma.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- EGFR - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of EGFR-mutated cancers)
- Diagnosed incident cases of EGFR-mutated cancer
- Diagnosed incident cases of EGFR-mutated NSCLC
- Diagnosed incident cases of EGFR-mutated SCLC
- Diagnosed incident cases of EGFR-mutated SCCHN
- Diagnosed incident cases of EGFR-mutated breast cancer
- Diagnosed incident cases of EGFR-mutated colorectal cancer
- Diagnosed incident cases of EGFR-mutated glioblastoma
- Diagnosed recurrent incident cases of EGFR-mutated cancer
- Diagnosed EGFR-mutated cancer 1st line drug-treatable population
- Diagnosed EGFR-mutated NSCLC 1st line drug-treatable population
- Diagnosed EGFR-mutated SCLC 1st line drug-treatable population
- Diagnosed EGFR-mutated SCCHN 1st line drug-treatable population
- Diagnosed EGFR-mutated breast cancer 1st line drug-treatable population
- Diagnosed EGFR-mutated colorectal cancer 1st line drug-treatable population
- Risk/protective factors applied to disease forecast models
- Reference Materials
